A variation of a 2-in-1 adaptive design to seamlessly expand a selected dose from a phase 2 trial to a phase 3 trial for oncology drug development
- Resource Type
- Short Communication
- Source
- In
Contemporary Clinical Trials April 2023 127 - Subject
- Language
- ISSN
- 1551-7144